I agree. The list is tough but fair...
I still see
I agree. The list is tough but fair...
I still see through a tiny window of opportunity in our CD-12 extension. The FDA wouldn’t of granted us an extension unless they hoped they would get us to an EUA. So please explain the reasoning that they would give us an extension for any other reason? It’s like they said... well 62 patients and iffy results don’t add up to enough confidence for us to take it to my boss and then their boss to seek an EUA. If we knocked it out of the park with 62 people... ok... let’s argue about it.
I find it reassuring that the FDA gave us this opportunity to improve our results and achieve efficacy and trial strength for our CD-15 trial. That’s huge in my book. They could of done so much worse. Tell to start over. Raise our patient count to a 1000. Yet here we stand complaining about anything and everything from the past. Not that there isn’t everyone’s right to complain.
My thoughts are did we hit 70 people and what day was that so we can count down the 28 days and then estimate the ability to gather the information on those people. If it happened a week or two ago that we hit 55 people then have we hit 70 already this past week? When do we start the clock on the fastest way for us to achieve an EUA? Is Nader going to update us on the 70 people they deemed necessary to achieve EUA? Is Nader playing this card close to his chest for nobody to see? Or will he say we have hit that number now and in 28 days we will have those great results we talked about in the 16.7% mortality. Sometimes we just have to read between the lines. The lines can be blurry.
The quickest approval for EUA in the USA is this journey I just laid out for us. It’s not over on the CD-12 trial just yet. We have not been turned down. We have been told to show us better results in an extension and we will consider you. That is another chance to set the age gap evenly and to somehow average the rather higher than normal placebo mortality that nobody expected. If our 70 patients average results to more normal expectations. Then we are in great shape in my opinion.
This is our big chance and some of you just can’t see it. Let hope the extension is our first of many successes.
It is for the benefit of all of us to take a step back and see the big picture of what is transpiring. There has to be a reason we haven’t broken down the door on a new protocol after having one submitted and approved then we just tread water for what? It’s like throwing pasta at the wall to see if it will stick. We are doing the ground work for more trials it seems but do we really want to do more? How close are we now to knowing the results of the 70 patients? 5 weeks? 6 weeks? Less? More? Only time will tell. It is our fastest path in the USA for an EUA. Let’s hope for the best and not dwell on the past. We have things to look forward to. Looking back isn’t the brightest picture for t he longs. I know because when I invested the HIV BLA was suppose to be files in a month in Sept. 2019. That didn’t happen. It took until June 2020. Then you know the rest of the story.
This was no way directed at you Bored Lawyer... I agreed then went much further than I thought I would. It always seems like I have much to say. Sorry...
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Turning Power into Potential at Union County Next stop, Union County, Arkansas. Z Squared Inc. (Nasdaq: ZSQR) isn't just talking shop; they're getting down to work. With a freshly acquired site through Paradox Data, LLC, Z Squared's planning to turn vision into reality. The site's already armed with 8 MW of juice, all ready to roll, but their ambitions shoot up to 150 MW...
Continue Reading
SCI's Rough Ride: Investors Brace for Impact There's nothing like waking up to find the stock you were banking on took a nosedive while you were dreaming of dividends. Service Corporation International (NYSE: SCI) sure gave shareholders more of a nightmare than a dream, slashing its earnings forecast for 2026 and watching its stock crumble by about 11.6% on October 29....
Continue Reading
Athens Networking Event: A Prelude to EXPO 2027 Buzzing with energy and the clinking of glasses, a meeting in Athens is doing what business folks love best—schmoozing and planning. Greek and Serbian representatives gathered up to lay the groundwork for EXPO 2027 Belgrade, and boy, was it all business. But hey, in our money-driven world, biz doesn't wait for Expo days to...
Continue Reading
Unseen Assets: The Untapped Wealth of Trade Secrets Ever pondered the real goldmine buried in your company's files? Mary Guzman certainly has, and she's cooked up a way to protect it. Guzman, the brain behind Crown Jewel Insurance, aims to shine a spotlight on those 'hidden gem' trade secrets that businesses often overlook. As the world increasingly turns intangible, it's...
Continue Reading
YSS Investors Navigate Legal Waters as Class Action Looms Taking a slug of coffee this morning and diving right into it—York Space Systems has found itself in hot water. They went public earlier this year with what was supposed to be a shining opportunity under the NYSE:YSS ticker, but it turns out that not everything in their IPO shined—and now SBS Law is stepping up...
Continue Reading
A Look at Where Policies Stumble Life's got no script for chaos, and you'd think the laws meant to protect folks from domestic violence would at least have a solid plan. Turns out, that's not always the case. Bloomberg Law just pulled back the curtain in a stinging investigation that exposes the gaping holes in these well-meaning policies. Why spill my morning coffee over...
Continue Reading
Human Milk-Derived Antibodies: The New Vanguard Out of the blue, here we are talking about human milk-derived antibodies as an answer to the pesky scourge of respiratory viruses. Lactiga US, Inc. has unfolded research that might reshape how we perceive treatments for those with compromised immune systems. Their daring leap into science, backed by McMaster University,...
Continue Reading
Coffee's brewing hot, and so are the stakes at ACTEC, where 55 new Fellows just got the nod. The American College of Trust and Estate Counsel isn't your average club. They've been at this game since 1949, bringing together the finest minds in trusts and estates. But what does this newest batch bring to the table, and why should investors take a moment to notice? A Diverse...
Continue Reading
A New Powerhouse in Roofing Services? Take a seat, folks—we're talking about a regional shakeup in the world of roofing and exterior building. ACACIA Exterior Building Group, based out of Alexandria, Virginia, just tightened its grip on the Mid-Atlantic and Gulf Coast markets by investing in Bel-Mac Roofing and Seashore Construction. This ain't just your run-of-the-mill...
Continue Reading
Fresh Faces Drive Change in Community Colleges There's a new crew in town, calling the shots on how North Carolina's community colleges operate. Ten spunky students across the state are now in the driver's seat, ready to give the old system a tune-up. It's about time someone got serious about what students need from their college experience, and the North Carolina...
Continue Reading
Top 5 Most Recently Viewed Articles
Broadridge Forms Strategic Partnership with Uptiq In a significant move to enhance wealth management, Broadridge Financial Solutions, Inc. (NYSE: BR) has announced a strategic partnership with Uptiq, a revolutionary AI platform tailored for financial services. This collaboration aims to integrate cutting-edge technology into Broadridge's Wealth Lending Network (WLN),...
Continue Reading
Camden Property Trust Earnings Overview Camden Prop Trust (NYSE: CPT) is gearing up for its upcoming quarterly earnings announcement. Investors and market analysts are preparing for this significant event, which is expected to provide a clearer picture of the company's financial health. The anticipation surrounds the forecasted earnings per share (EPS), estimated at...
Continue Reading
Understanding Shareholder Rights and Investigations Investors often find themselves navigating the complex world of corporate transactions and mergers. Halper Sadeh LLC, a prominent law firm focused on investor rights, is actively seeking to protect shareholders of several companies that are currently undergoing significant corporate changes and potential acquisitions....
Continue Reading
Almaden Minerals Pursues Damages Claim Against Mexico In an impactful move reflecting its commitment to safeguarding its interests, Almaden Minerals Ltd. (TSX: AMM; OTCQB: AAUAF) has recently filed a significant memorial submission in the context of international arbitration proceedings. This legal action, initiated due to supposed breaches by Mexico under the...
Continue Reading
VF Corporation Faces Class Action Lawsuit VF Corporation, often recognized by its ticker symbol VFC, is currently involved in a significant class action lawsuit. This lawsuit, spearheaded by Pomerantz LLP, focuses on allegations of securities fraud and potentially unlawful business practices exercised by the company's officers and directors. Contacting Legal...
Continue Reading